Elisabetta Castoldi Selected Research

Activated Protein C Resistance (APC Resistance)

8/2014	Fibrinogen γ' increases the sensitivity to activated protein C in normal and factor V Leiden plasma.
4/2014	FV and APC resistance: the plot thickens.
1/2012	Genetic modulation of the FV(Leiden)/normal FV ratio and risk of venous thrombosis in factor V Leiden heterozygotes.
1/2009	Factor V Leiden and activated protein C resistance.
11/2008	Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.
2/2006	Protein S levels modulate the activated protein C resistance phenotype induced by elevated prothrombin levels.
10/2005	An underestimated combination of opposites resulting in enhanced thrombotic tendency.
6/2004	Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations.
5/2004	Factor V Leiden: a disorder of factor V anticoagulant function.
10/2003	Endogenous factor V synthesis in megakaryocytes contributes negligibly to the platelet factor V pool.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Elisabetta Castoldi Research Topics

Disease

12	Activated Protein C Resistance (APC Resistance) 08/2014 - 09/2002
11	Venous Thrombosis (Deep-Vein Thrombosis) 04/2016 - 05/2004
9	Thrombosis (Thrombus) 01/2021 - 05/2004
9	Hemorrhage 01/2020 - 12/2003
5	Venous Thromboembolism 01/2021 - 06/2003
3	Thrombophilia 01/2021 - 10/2005
3	Factor V Deficiency 11/2013 - 11/2008
3	Protein S Deficiency (Deficiency, Protein S) 09/2010 - 09/2008
2	Disease Susceptibility (Diathesis) 01/2009 - 11/2008
1	Thrombotic Microangiopathies 07/2020
1	Hemophilia A (Haemophilia) 07/2020
1	Infections 07/2020
1	Inflammation (Inflammations) 07/2020
1	Neoplasms (Cancer) 07/2020
1	Scott Syndrome 02/2016
1	Essential Thrombocythemia 11/2008
1	Polycythemia Vera 11/2008

Drug/Important Bio-Agent (IBA)

13	Factor V (Coagulation Factor V)IBA 07/2020 - 09/2002
11	factor V LeidenIBA 01/2020 - 06/2003
10	Protein CIBA 01/2020 - 10/2003
9	Thrombin FDA Link 02/2011 - 12/2003
6	Protein SIBA 01/2021 - 02/2006
6	AnticoagulantsIBA 07/2020 - 05/2004
3	Proteins (Proteins, Gene)FDA Link 02/2016 - 02/2006
2	ThrombomodulinIBA 01/2020 - 02/2015
2	Thromboplastin (Tissue Factor)IBA 01/2020 - 01/2012
2	Prothrombin (Factor II)IBA 02/2015 - 02/2006
2	lipoprotein-associated coagulation inhibitor (TFPI)IBA 01/2010 - 11/2008
1	Factor VIII (Coagulation Factor VIII)IBA 01/2021
1	A-factor (Streptomyces)IBA 01/2021
1	Hemostatics (Antihemorrhagics)IBA 07/2020
1	von Willebrand FactorIBA 07/2020
1	FibrinIBA 01/2020
1	Toll-Like Receptor 9IBA 04/2016
1	Ion Channels (Ion Channel)IBA 02/2016
1	CollagenIBA 02/2016
1	PhosphatidylserinesIBA 02/2016
1	AnoctaminsIBA 02/2016
1	CalpainIBA 02/2016
1	Fibrinogen (Factor I)FDA Link 08/2014
1	Peptides (Polypeptides)IBA 08/2014
1	Amino Acids FDA Link 04/2014
1	RNA (Ribonucleic Acid)IBA 11/2013
1	platelet factor VIBA 01/2010
1	Vitamin K FDA Link 09/2008
1	Protein Isoforms (Isoforms)IBA 09/2002

Therapy/Procedure

1	Therapeutics 11/2013